| Dr Elizabeth Jeannie Wilson-ward, MD, FACEP | |
|
3621 S Emerald Dr, Wausau, WI 54401-3962 | |
| (715) 845-9805 | |
| Not Available |
| Full Name | Dr Elizabeth Jeannie Wilson-ward |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 38 Years |
| Location | 3621 S Emerald Dr, Wausau, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467759498 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 30770 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspirus Riverview Hospital & Clinics Inc | Wisconsin rapids, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aspirus Riverview Hospital And Clinics Inc | 4587658182 | 144 |
News Archive
AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
New data confirm that subcutaneous injection of the innovative new anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) delivers rapid, sustained and stable correction of anemia in a broad spectrum of patients with chronic kidney disease at dosing intervals of up to 4 weeks.
Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.
Evidence of resistance to the antimalarial drug artemisinin and its derivatives threatens efforts to control malaria in Southeast Asia, and experts fear artemisinin resistance may spread from the Thailand-Cambodia border to affect other malaria endemic countries. Evidence to such effect was presented today at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
› Verified 6 days ago
| Entity Name | Aspirus Riverview Hospital & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295754844 PECOS PAC ID: 4587658182 Enrollment ID: O20040414000945 |
News Archive
AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
New data confirm that subcutaneous injection of the innovative new anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) delivers rapid, sustained and stable correction of anemia in a broad spectrum of patients with chronic kidney disease at dosing intervals of up to 4 weeks.
Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.
Evidence of resistance to the antimalarial drug artemisinin and its derivatives threatens efforts to control malaria in Southeast Asia, and experts fear artemisinin resistance may spread from the Thailand-Cambodia border to affect other malaria endemic countries. Evidence to such effect was presented today at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elizabeth Jeannie Wilson-ward, MD, FACEP 3621 S Emerald Dr, Wausau, WI 54401-3962 Ph: (715) 845-9805 | Dr Elizabeth Jeannie Wilson-ward, MD, FACEP 3621 S Emerald Dr, Wausau, WI 54401-3962 Ph: (715) 845-9805 |
News Archive
AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
New data confirm that subcutaneous injection of the innovative new anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) delivers rapid, sustained and stable correction of anemia in a broad spectrum of patients with chronic kidney disease at dosing intervals of up to 4 weeks.
Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.
Evidence of resistance to the antimalarial drug artemisinin and its derivatives threatens efforts to control malaria in Southeast Asia, and experts fear artemisinin resistance may spread from the Thailand-Cambodia border to affect other malaria endemic countries. Evidence to such effect was presented today at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
› Verified 6 days ago
Stewart Michael Wente, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Winston D Ryan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Bartholomew D Hobson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2727 Plaza Dr, Wausau, WI 54401 Phone: 715-847-3000 | |
Dr. Andrew Joseph Stoltze, M.D., J.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Mark J Mirick, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Paul Gill, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2160 |